G protein-coupled receptors in rheumatology

Nature Reviews Rheumatology

Volumn 10, Issue 7, 2014, Pages 429-436

  Neumann, Elena ^a   Khawaja, Kiran ^a   Müller Ladner, Ulf ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; BRADYKININ B2 RECEPTOR; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C5A RECEPTOR; D6 RECEPTOR; EOTAXIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; PROTEINASE ACTIVATED RECEPTOR; SCAVENGER RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

G-PROTEIN-COUPLED RECEPTOR KINASES; GUANINE NUCLEOTIDES; HUMANS; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOSPHINGOLIPID; RECEPTORS, PROTEINASE-ACTIVATED; RECEPTORS, PURINERGIC P1; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 84903742102     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.62     Document Type: Review

References (60)

1. Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639Y650 (2002
2. Venkatakrishnan, A. J. et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185Y194 (2013
3. Hutchings, C. J., Koglin, M. & Marshall, F. H. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2, 594Y606 (2010
4. Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739Y745 (2000
5. Cherezov, V. et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318, 1258Y1265 (2007
6. Katritch, V., Cherezov, V. & Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531Y556 (2013
7. Katritch, V., Cherezov, V. & Stevens, R. C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33, 17Y27 (2012
8. Steyaert, J. & Kobilka, B. K. Nanobody stabilization of G protein-coupled receptor conformational states. Curr. Opin. Struct. Biol. 21, 567Y572 (2011
9. Latek, D., Modzelewska, A., Trzaskowski, B., Palczewski, K. & Filipek, S. G protein-coupled receptors - recent advances. Acta Biochim. Pol. 59, 515Y529 (2012
10. Giguere, P. M., Laroche, G., Oestreich, E. A. & Siderovski, D. P. G-protein signaling modulator-3 regulates heterotrimeric G-protein dynamics through dual association with Gβ and Gαi protein subunits. J. Biol. Chem. 287, 4863Y4874 (2012
11. Wettschureck, N. & Offermanns, S. Mammalian G proteins and their cell type specific functions. Physiol. Rev. 85, 1159Y1204 (2005
12. Zhao, A. et al. Gαo represses insulin secretion by reducing vesicular docking in pancreatic β-cells. Diabetes 59, 2522Y2529 (2010
13. Choudhury, S. R., Bisht, N. C., Thompson, R., Todorov, O. & Pandey, S. Conventional and novel Gγ protein families constitute the heterotrimeric G-protein signaling network in soybean. PLoS ONE 6, e23361 (2011
14. Shukla, A. K. et al. Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 497, 137Y141 (2013
15. Lombardi, M. S. et al. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB J. 13, 715Y725 (1999
16. Lombardi, M. S. et al. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J. Immunol. 166, 1635Y1640 (2001
17. Frommer, K. W. et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum. 62, 2886Y2899 (2010
18. Penela, P. et al. G protein-coupled receptor kinase 2 (GRK2) in migration and inflammation. Arch. Physiol. Biochem. 114, 195Y200 (2008
19. Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916Y920 (2001
20. Kinsel, J. F. & Sitkovsky, M. V. Possible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands. Ann. Rheum. Dis. 62 (Suppl. 2), ii22Yii24 (2003
21. Suarez-Almazor, M. E., Belseck, E., Shea, B., Wells, G. & Tugwell, P. Methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000957. http://dx.doi.org/10.1002/14651858.CD000957
22. Wessels, J. A., Huizinga, T. W. & Guchelaar, H. J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47, 249Y255 (2008
23. Tian, H. & Cronstein, B. N. Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt Dis. 65, 168Y173 (2007
24. Montesinos, M. C. et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48, 240Y247 (2003
25. Jacobson, K. A., Balasubramanian, R., Deflorian, F. & Gao, Z. G. G protein-coupled adenosine (P1) and P2Y receptors: Ligand design and receptor interactions. Purinergic Signal. 8, 419Y436 (2012
26. David, M. et al. Treatment of plaque-type psoriasis with oral CF101: Data from an exploratory randomized phase 2 clinical trial. J. Eur. Acad. Dermatol. Venereol. 26, 361Y367 (2012
27. Murphy, P. M. et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145Y176 (2000
28. Szekanecz, Z., Vegvari, A., Szabo, Z. & Koch, A. E. Chemokines and chemokine receptors in arthritis. Front. Biosci. (Schol. Ed.) 2, 153Y167 (2010
29. Neumann, E., Lefevre, S., Zimmermann, B., Gay, S. & Müller-Ladner, U. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol. Med. 16, 458Y468 (2010
30. O'Boyle, G., Mellor, P., Kirby, J. A. & Ali, S. Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J. 23, 3906Y3916 (2009
31. Johnson, Z. et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. 173, 5776Y5785 (2004
32. Ali, S. et al. A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J. Immunol. 175, 1257Y1266 (2005
33. Ali, S., Fritchley, S. J., Chaffey, B. T. & Kirby, J. A. Contribution of the putative heparan sulfate-binding motif BBXB of RANTES to transendothelial migration. Glycobiology 12, 535Y543 (2002
34. Yellin, M. et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1730Y1739 (2012
35. Hatse, S., Princen, K., Bridger, G., De Clercq, E. & Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527, 255Y262 (2002
36. Garcia-Vicuna, R. et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 50, 3866Y3877 (2004
37. Chen, H. T. et al. Stromal cell-derived factor-1/CXCR4 promotes IL-6 production in human synovial fibroblasts. J. Cell. Biochem. 112, 1219Y1227 (2011
38. Matthys, P. et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J. Immunol. 167, 4686Y4692 (2001
39. Li, Y et al. Influence on matrix metalloproteinases 3, 9, and 13 levels after blocking stromal cell derived factor 1/chemokine receptor 4 signaling pathway with AMD3100 [Chinese]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 26, 652Y656 (2012
40. Wei, F. et al. Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway. Arthritis Res. Ther. 14, R177 (2012
41. Vergunst, C. E. et al. Modulation of CCR2 in rheumatoid arthritis: A double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58, 1931Y1939 (2008
42. Fleishaker, D. L. et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res. Ther. 14, R11 (2012
43. Singh, M. D. et al. Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. Am. J. Pathol. 181, 1158Y1164 (2012
44. Lindberg, M. Use of NSAIDs in rheumatoid arthritis should be limited [Danish]. Ugeskr. Laeger 175, 1039Y1041 (2013
45. Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T. & Lichtman, A. H. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol. Biochem. Behav. 99, 718Y725 (2011
46. Laragione, T., Brenner, M., Sherry, B. & Gulko, P. S. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum. 63, 3274Y3283 (2011
47. Chao, P. Z., Hsieh, M. S., Cheng, C. W., Lin, Y. F. & Chen, C. H. Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes. J. Biomed. Sci. 18, 86 (2011
48. Flytlie, H. A. et al. Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Cytokine 49, 24Y29 (2010
49. Bellucci, F. et al. Novel effects mediated by bradykinin and pharmacological characterization of bradykinin B2 receptor antagonism in human synovial fibroblasts. Br. J. Pharmacol. 158, 1996Y2004 (2009
50. Leeb-Lundberg, L. M., Marceau, F., Muller-Esterl, W., Pettibone, D. J. & Zuraw, B. L. International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27Y77 (2005
51. Song, I. H. et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann. Rheum. Dis. 68, 75Y83 (2009
52. Meini, S. et al. Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E2 release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes. Naunyn Schmiedebergs Arch. Pharmacol. 385, 777Y786 (2012
53. Sarma, J. V. & Ward, P. A. New developments in C5a receptor signaling. Cell Health Cytoskelet. 4, 73Y82 (2012
54. Fairlie, D & Sheils, I. A. Treatment of osteoarthritis: EP 1575606 A1 [online], http://www.google.com/patents/EP1575606A1?cl=en (2005
55. Rosen, H., Stevens, R. C., Hanson, M., Roberts, E. & Oldstone, M. B. Sphingosine-1-phosphate and its receptors: Structure, signaling, and influence. Annu. Rev. Biochem. 82, 637Y662 (2013
56. Tsunemi, S. et al. Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin. Immunol. 136, 197Y204 (2010
57. Zu Heringdorf, D. M., Ihlefeld, K. & Pfeilschifter, J. Pharmacology of the sphingosine-1-phosphate signalling system. Handb. Exp. Pharmacol. 215, 239Y253 (2013
58. Graler, M. H. Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. Cell. Physiol. Biochem. 26, 79Y86 (2010
59. Ferrell, W. R., Kelso, E. B., Lockhart, J. C., Plevin, R. & McInnes, I. B. Protease-activated receptor 2: A novel pathogenic pathway in a murine model of osteoarthritis. Ann. Rheum. Dis. 69, 2051Y2054 (2010
60. Chen, T. L. et al. Anti-inflammatory mechanisms of the proteinase-activated receptor 2-inhibiting peptide in human synovial cells. J. Biomed. Sci. 18, 43 (2011.